Fujisawa Micafungin Safety, Prophylatic Use Could Be Benefits Vs. Cancidas
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Fujisawa is looking to differentiate its I.V. echinocandin antifungal agent, micafungin, from Merck’s Cancidas by indications and safety profile.
You may also be interested in...
Pfizer Vfend Sets New Efficacy Standard In Invasive Aspergillosis, FDA Says
Vfend’s marked efficacy in invasive aspergillosis makes the Pfizer antifungal attractive as an active comparator in studies for the indication, FDA review documents suggest.
Pfizer Vfend Cardiac Safety Studies Needed For Esophageal Candida Approval
Approval of Pfizer’s Vfend for treatment of esophageal candidiasis depends on completion of cardiac studies to rule out an unacceptable risk of QTc prolongation, review documents for the triazole antifungal indicate.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011